{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Pancreatic+Cancer", "query": { "condition": "Metastatic Pancreatic Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 845, "total_pages": 85, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Pancreatic+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T10:29:11.917Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04068896", "title": "Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Metastatic Castration-resistant Prostate Cancer", "Bladder Cancer", "Melanoma", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Gastric Cancer", "Esophageal Cancer", "Ovarian Cancer", "Head Neck Squamous Cell Carcinoma", "Prostate Cancer" ], "interventions": [ { "name": "NGM120 30mg", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg", "type": "BIOLOGICAL" }, { "name": "NGM120 30mg with Gemcitabine and Abraxane", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg with Gemcitabine and Abraxane", "type": "BIOLOGICAL" }, { "name": "NGM120 100mg Q3W", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2019-10-16", "completion_date": "2024-01-08", "has_results": true, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-06-07T10:29:11.917Z", "location_count": 20, "location_summary": "Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068896" }, { "nct_id": "NCT05052723", "title": "Cabozantinib and Pembrolizumab in Metastatic Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joseph Kim", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 21, "start_date": "2022-01-04", "completion_date": "2024-11-05", "has_results": true, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-06-07T10:29:11.917Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT05052723" }, { "nct_id": "NCT02231723", "title": "A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "BBI608", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "MM-398", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2014-08", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-06-07T10:29:11.917Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02231723" }, { "nct_id": "NCT04426669", "title": "A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Epithelial Cancer", "Gastrointestinal Neoplasms", "Cancer of Gastrointestinal Tract", "Cancer, Gastrointestinal", "Gastrointestinal Cancer", "Colo-rectal Cancer", "Pancreatic Cancer", "Gall Bladder Cancer", "Colon Cancer", "Esophageal Cancer", "Stomach Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Tumor-Infiltrating Lymphocytes (TIL)", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Intima Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 23, "start_date": "2020-05-15", "completion_date": "2026-01-22", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-06-07T10:29:11.917Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04426669" }, { "nct_id": "NCT03086369", "title": "A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Olaratumab", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2017-06-22", "completion_date": "2021-06-17", "has_results": true, "last_update_posted_date": "2022-06-28", "last_synced_at": "2026-06-07T10:29:11.917Z", "location_count": 32, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 26 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03086369" }, { "nct_id": "NCT04753879", "title": "Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2021-09-29", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-06-07T10:29:11.917Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04753879" }, { "nct_id": "NCT00428597", "title": "A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Islet Cell", "Carcinoma, Pancreas" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 171, "start_date": "2007-06", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2010-10-11", "last_synced_at": "2026-06-07T10:29:11.917Z", "location_count": 14, "location_summary": "Aurora, Colorado • Iowa City, Iowa • Worcester, Massachusetts + 6 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "City of Saint Peters", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00428597" }, { "nct_id": "NCT06199466", "title": "A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "YL-13027", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2024-01-22", "completion_date": "2025-09-15", "has_results": false, "last_update_posted_date": "2025-12-08", "last_synced_at": "2026-06-07T10:29:11.917Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06199466" }, { "nct_id": "NCT04098081", "title": "1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Pancreatic Cancer" ], "interventions": [ { "name": "galeterone", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2019-12-12", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-06-07T10:29:11.917Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04098081" }, { "nct_id": "NCT05169437", "title": "Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Breast Tumor", "Colon Tumor, Malignant", "Lung Tumor", "Urologic Cancer", "Pancreatic Cancer", "Melanoma", "Metastatic Cancer", "Locally Advanced Solid Tumor", "Esophageal Cancer", "Endometrial Cancer", "Head and Neck Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tempus AI", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-03-15", "completion_date": "2024-08-27", "has_results": true, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-06-07T10:29:11.917Z", "location_count": 80, "location_summary": "Yuma, Arizona • Springdale, Arkansas • Fountain Valley, California + 69 more", "locations": [ { "city": "Yuma", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05169437" } ] }